Oct 6, 2025 · Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.

Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications …

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical …

At Harrow, our values aren’t just guiding words—they shape how we grow, innovate, and work together. Humility, ownership, preparedness, and entrepreneurship create the foundation for a …

In September 2025, Harrow announced the launch of Harrow Access for All (HAFA), expanding Harrow’s commitment to make it easier and more affordable for patients to access Harrow’s …

Harrow INC SEC filing: Form 8-K iXBRL on 09/09/2025 (0001493152-25-012840).

Dec 31, 2024 · Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic …

November 24, 2025 Harrow to Present at Two Investor Conferences in December November 18, 2025 Harrow Announces Closing of Acquisition of Melt Pharmaceuticals November 10, 2025 …

The HarrowAccess.com portal will offer access to Harrow’s portfolio of specialty, generic, and compounded ophthalmic medications and Harrow-affiliated partner products.

The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.